← All Clearmind Medicine INC filings

Clearmind Medicine INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
CMND
Clearmind Medicine INC
20-F: Clearmind Medicine Advances Psychedelic Therapies Amidst Financial Challenges
Clearmind Medicine Inc. reports progress in its Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder, despite ongoing significant net losses and a going concern warning.
NASDAQ
CMND
Clearmind Medicine INC
20-F: Clearmind Medicine Inc. Files 20-F Annual Report, Highlighting Clinical Trial Progress and Financial Results
Clearmind Medicine Inc. releases its 20-F annual report, detailing progress in clinical trials for MEAI-based treatments and providing an overview of its financial performance.
NASDAQ
CMND
Clearmind Medicine INC
20-F/A: Clearmind Medicine Files Amendment to Annual Report to Include Executive Certifications
Clearmind Medicine Inc. files an amendment to its annual report on Form 20-F to include certifications from the CEO and CFO as required by the Securities Exchange Act.
NASDAQ
CMND
Clearmind Medicine INC
20-F/A: Clearmind Medicine Files Amendment to 20-F Annual Report Addressing Accounting Adjustments
Clearmind Medicine Inc. files an amendment to its annual report to revise the report of the predecessor Independent Public Accounting Firm and re-issue the report of the Independent Registered Public Accounting Firm regarding retrospective adjustments to financial information.
NASDAQ
CMND
Clearmind Medicine INC
20-F: Clearmind Medicine Inc. Files 20-F Annual Report, Details Executive Clawback Policy
Clearmind Medicine Inc. releases its 20-F filing, outlining financial results, business overview, and an executive officer clawback policy.